Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine

Expert Opinion on Drug Safety

Volumn 13, Issue 1, 2014, Pages 131-138

  Doggrell, Sheila A ^a   Hancox, Jules C ^b  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antiemetic; Cardiac safety; Domperidone; Galactogogue; Gastroparesis; Proarrhythmia; Prokinetic; QT interval; Torsades de pointes

Indexed keywords

ANTIEMETIC AGENT; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450 3A4; DOMPERIDONE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; FLUCONAZOLE; GALACTOGOGUE; KETOCONAZOLE; METOCLOPRAMIDE; PLACEBO; POTASSIUM CHANNEL HERG; PROKINETIC AGENT; PROLACTIN;

ADULT; ARRHYTHMOGENESIS; ARTICLE; AUSTRALIA; BRADYCARDIA; BREAST FEEDING; CARDIOTOXICITY; CASE CONTROL STUDY; CHILD; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ECG ABNORMALITY; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HEALTH HAZARD; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LACTATION; LONG QT SYNDROME; NAUSEA AND VOMITING; NONHUMAN; PARKINSON DISEASE; POPULATION RESEARCH; POSTOPERATIVE NAUSEA AND VOMITING; PROLACTIN RELEASE; QT INTERVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; RISK FACTOR; STOMACH PARESIS; SUDDEN CARDIAC DEATH; TORSADE DES POINTES; UNITED STATES;

ADMINISTRATION, ORAL; ANIMALS; ANTIEMETICS; DOMPERIDONE; FEMALE; GALACTOGOGUES; HEART DISEASES; HUMANS; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84890479603     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.851193     Document Type: Article

References (62)

1. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 1999;33:429-40 (Pubitemid 29215810)
2. FDA Talk Paper: FDA warns against women using unapproved drug, domperidone, to increase mild production. Available from: http://www. fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm173886. htm [Accessed 13 June 2013]
3. FDA Safety Alert: for Human Medical Products: Domperidone. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsfor HumanMedicalProducts/ucm154914.htm [Accessed 13 June 2013
4. European Medicines Agency: Review of domperidone started. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/ Domperidone-31/Procedure-started/WC500139769.pdf [Accessed 13 June 2013]
5. Joss RA, Goldhirsch A, Brunner KW, Galeazzi RL. Sudden death in cancer patient on high-dose domperidone. Lancet 1982;1:1019 (Pubitemid 12146415)
6. Roussak JR, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. BMJ 1984;289:1579 (Pubitemid 15220621)
7. Giaccone G, Bertetto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet 1984;2:1336-7 (Pubitemid 15176817)
8. Osborne RJ, Slevin ML, Hunter RW, et al. Cardiotoxicity of intravenous domperidone. Lancet 1985;2:385.
9. Osborne RJ, Slevin ML, Hunter RW, Hamer J. Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Hum Toxicol 1985;4:617-26
10. Quinn N, Parkes D, Jackson G, et al. Cardiotoxicity of domperidone. Lancet 1985;2:724; Letter (Pubitemid 15244969)
11. Cameron HA, Reyntjiens AJ, Lake-Bakaar G, et al. Cardiac arrest after treatment with intravenous domperidone. BMJ 1985;290:160 Letter (Pubitemid 15122971)
12. Bruera E, Villamayor R, Roca E, et al. QT interval prolongation and ventricular fibrillation with i.v. domperidone. Cancer Treat Rep 1986;70:545-6 (Pubitemid 16116472)
13. Meuldermans W, Hurkmands R, Swysen E, et al. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmackinet 1981;6:49-60 (Pubitemid 11104423)
14. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007;102:2036-45 (Pubitemid 47301500)
15. Huang YC, Colaizzi JL, Bierman RH, et al. Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol 1988;26:628-32
16. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol 2012;73:411-21
17. Heykants J, Hendriks R, Meuldermans M, et al. On the pharmacokinetics of domperidone in animals and man IV. The pharmacokinetics of intravenous domperidone and its bioavailablity in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmackinet 1981;6:61-70 (Pubitemid 11104424)
18. Wan EW, Davey K, Page-Sharp M, et al. Dose-effect study of domperidone as a galactogogue in preterm mothers with insufficient milk supply, and its transfer into milk. Br J Clin Pharmacol 2008;66:283-9
19. Ward BA, Morocho A, Kandil A, et al. Characterization of human cytochrome P450 enzymes catalysing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 2004;58:277-87 (Pubitemid 39209061)
20. Michaud V, Turgeon J. Assessment of competitive and mechanism-based inhibitor by clarithromycin: use of domperidone as a CYP3A probe-drug substrate and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes. Drug Metab Lett 2010;4:69-76
21. Michaud V, Simard C, Turgeon J. Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b(5) and inhibition by ketoconazole. Drug Metab Lett 2010;4:95-10320
22. Davis RH, Clench MH, Mathias JR. Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study. Dig Dis Sci 1988;33:1505-11 (Pubitemid 19095450)
23. Roy P, Patel NH, Miller AJ. A comparison of controlled release metoclopramide and domperidone in the treatment of nausea and vomiting. Br J Clin Pract 1991;45:247-51
24. Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicentre controlled trial. DOM-USA-5 Study Group. Clin Ther 1998;20:438-53 (Pubitemid 28343497)
25. Patterson D, Abell T, Rothstein R, et al. A double-blind multicentre comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230-4 (Pubitemid 29214634)
26. Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 2006;6:571-6 (Pubitemid 44660947)
27. Suqumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol 2008;6:726-33
28. Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesphageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005;59:725-9 (Pubitemid 40835508)
29. Hegar B, Alatas S, Advanti N, et al. Domperidone versus cisapride in the treatment of infant regurgitation and increased acid gastro-oesphageal reflux: a pilot study. Acta Paediatr 2009;98:750-5
30. Petraglia F, de Leo V, Sardelli S, et al. Domperidone in defective and insufficient lactation. Eur J Obstet Gynecol Reprod Biol 1985;19:281-7 (Pubitemid 15075559)
31. Da Silva OP, Knoppert DC, Angelini MM, Forret PA. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial. CMAJ 2001;164:17-21 (Pubitemid 32094879)
32. Jantarasaengaram S, Sreewapa S. Effect of domperidone on augmentation of lactation following cesarean delivery at full term. Int J Gynaecol Obstet 2012;116:240-3
33. Zuppa AA, Sindico P, Orchi C, et al. Safety and efficacy of galactogogues: substances that maintain and increase breast milk production. J Pharm Pharm Sci 2010;13:162-74
34. Osadchy A, Moretti ME, Koren G. Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-Analysis of randomized controlled trials. Obstet Gynecol Int 2012;doi:10.1155/2012/642893
35. Ingram J, Taylor H, Churchill C, et al. Metoclopramide or domperidone for increasing maternal breast milk output: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2012;97:F241-5
36. Drolet B, Rousseau G, Daleau P, et al. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000;102(16):1883-520
37. Hreiche R, Morissette P, Zakrzewski-Jakubiak H, Turgeon J. Gender-related differences in drug-induced prolongation of cardiac repolarization in prepubertal guinea pigs. J Cardiovasc Pharmacol Ther 2009;14(1):28-37
38. Hondeghem LM. Domperidone: limited benefits with significant risk for sudden cardiac death. J Cardiovasc Pharmacol 2013;61(3):218-25 20
39. Claassen S, Zunkler BJ. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology 2005;74(1)
40. Stork D, Timin EN, Berjukow S, et al. State dependent dissociation of HERG channel inhibitors. Br J Pharmacol 2007;151:1368-76 (Pubitemid 47255915)
41. Hreiche R, Plante I, Drolet B, et al. Lengthening of cardiac repolarization in isolated guinea pigs hearts by sequential or concomitant administration of two IKr blockers. J Pharm Sci 2011;100(6):2469-81
42. Hancox JC, McPate MJ, El Harchi A, Zhang YH. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 2008;119:118-32
43. Gintant GA. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacol Ther 2008;119(2):199-209
44. Vargas HM. A new preclinical biomarker for risk of Torsades de Pointes: drug-induced reduction of the cardiac electromechanical window. Br J Pharmacol 2010;161(7):1441-3
45. Guns PJ, Johnson DM, Weltens E, Lissens J. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig. J Pharmacol Toxicol Methods 2012;66(2)
46. Hondeghem LM. Low safety index of domperidone: mechanism for increased odds ratio for sudden cardiac death. Acta Cardiol 2011;66(4):421-5
47. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovas Res 2003;58:32-45 (Pubitemid 36351620)
48. Rocha CMG, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005;26:720-3 (Pubitemid 43015826)
49. Djeddi D, Kongolo G, Lafaix C, et al. Effect of domperidone on QT interval in neonates. J Pediatr 2008;153:663-6
50. Gunlemez A, Babaog?lu A, Arisoy AE, et al. Effect of domperidone on the QTc interval in premature infants. J Perinatol 2010;30:50-3
51. Viera MC, Miyague NI, Van Steen K, et al. Effects of domperidone on QTc intervals. Acta Paediatr 2012;101:494-6
52. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-Antiarrhythmic drugs E14. Available from: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E14/E14-Guideline. pdf [Accessed 29th July 2013]
53. Djelouah I, Scott C. Domperidone: heart rate and rhythm disorders. Canadian Adv React Newslett 2007.17(1): 2. Available from: http://www.hc-sc.gc. ca/dhp-mps/alt-formats/pdf/medeff/bulletin/carn-bcei-v17n1-eng. pdf [Accessed 17th June 2013]
54. Digby G, MacHaalany J, Malik P, et al. Multifactorial QT interval prolongation. Cardiol J 2010;17:184-8
55. Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005;26:2007-12 (Pubitemid 41435722)
56. van Noord C, Dieleman JP, van Herpen G, et al Domperidone and ventricular arrhythmia or sudden cardiac death: a population-base case-control study in the Netherlands. Drug Saf 2010 33 1003-14
57. Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacepidemiol Drug Saf 2010;19:881-8
58. De Bruin ML, Langendijk PN, Koopmans RP. In-hospital cardiac arrest is associated with non-Antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol 2007;63:216-23 (Pubitemid 46072108)
59. Lightdale JR, Gremse DA. Gastroesphageal reflux: management guidance for the pediatrician. Pediatrics 2013;131:e1684-95
60. Bozzo P, Koren G, Ito S. Health Canada advisory on domperidone - should I avoid prescribing domperidone to women to increase milk production? Can Fam Physician 2012;58:952-3
61. Michaud V, Turgeon J. Domperidone and sudden cardiac death: how much longer should we wait? J Cardiovasc Pharmacol 2013;3:215-17
62. Domperidone: ventricular arrhythmia and sudden death (continued). Prescrire Int 2012;21:183 20